Lexeo Therapeutics (LXEO) Competitors $3.89 -0.14 (-3.47%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$3.89 0.00 (0.00%) As of 02/21/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LXEO vs. ORIC, RAPP, SEPN, PGEN, STOK, CGEM, AUTL, VALN, XERS, and MAZEShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), Precigen (PGEN), Stoke Therapeutics (STOK), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Valneva (VALN), Xeris Biopharma (XERS), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. ORIC Pharmaceuticals Rapport Therapeutics Septerna Precigen Stoke Therapeutics Cullinan Therapeutics Autolus Therapeutics Valneva Xeris Biopharma Maze Therapeutics Lexeo Therapeutics (NASDAQ:LXEO) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Does the media prefer LXEO or ORIC? In the previous week, ORIC Pharmaceuticals had 9 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 14 mentions for ORIC Pharmaceuticals and 5 mentions for Lexeo Therapeutics. ORIC Pharmaceuticals' average media sentiment score of 0.35 beat Lexeo Therapeutics' score of 0.33 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ORIC Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders & institutionals believe in LXEO or ORIC? 60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 4.5% of Lexeo Therapeutics shares are held by insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is LXEO or ORIC more profitable? ORIC Pharmaceuticals' return on equity of -44.54% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -57.66% -48.18% ORIC Pharmaceuticals N/A -44.54%-40.72% Do analysts rate LXEO or ORIC? Lexeo Therapeutics presently has a consensus target price of $23.80, suggesting a potential upside of 511.83%. ORIC Pharmaceuticals has a consensus target price of $18.71, suggesting a potential upside of 143.68%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lexeo Therapeutics is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, LXEO or ORIC? Lexeo Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K197.91-$66.39M-$3.16-1.23ORIC PharmaceuticalsN/AN/A-$100.70M-$1.82-4.22 Which has more risk and volatility, LXEO or ORIC? Lexeo Therapeutics has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Does the MarketBeat Community believe in LXEO or ORIC? ORIC Pharmaceuticals received 49 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 74.19% of users gave ORIC Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLexeo TherapeuticsOutperform Votes20100.00% Underperform VotesNo VotesORIC PharmaceuticalsOutperform Votes6974.19% Underperform Votes2425.81% SummaryORIC Pharmaceuticals beats Lexeo Therapeutics on 9 of the 17 factors compared between the two stocks. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$133.26M$3.11B$5.84B$9.15BDividend YieldN/A1.55%4.75%3.85%P/E Ratio-1.2327.4925.4719.00Price / Sales197.91329.47447.5876.30Price / CashN/A168.8738.0134.83Price / Book0.913.687.644.62Net Income-$66.39M-$71.72M$3.18B$245.85M7 Day Performance-13.56%-2.50%-1.99%-2.68%1 Month Performance-20.61%-0.32%-0.42%-2.19%1 Year Performance-75.53%-12.32%16.51%12.84% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics3.3573 of 5 stars$3.89-3.5%$23.80+511.8%-74.8%$133.26M$650,000.00-1.2358News CoverageORICORIC Pharmaceuticals4.5474 of 5 stars$8.36+1.1%$18.71+123.9%-25.6%$589.97MN/A-4.6480Earnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRAPPRapport Therapeutics1.8127 of 5 stars$15.90+0.8%$35.00+120.1%N/A$581.62MN/A0.00N/AUpcoming EarningsSEPNSepterna2.1659 of 5 stars$12.96+12.2%$43.67+236.9%N/A$575.42MN/A0.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpPGENPrecigen3.9524 of 5 stars$1.96-1.0%$7.00+257.1%+34.5%$574.03M$6.22M-3.56190Gap UpSTOKStoke Therapeutics3.7043 of 5 stars$10.68+0.5%$21.29+99.3%+55.4%$565.72M$8.78M-5.09100Analyst ForecastAnalyst RevisionNews CoverageCGEMCullinan Therapeutics2.3347 of 5 stars$9.53-0.6%$32.50+241.0%-47.1%$554.93MN/A-3.3630AUTLAutolus Therapeutics2.9227 of 5 stars$2.04+5.2%$10.40+409.8%-68.5%$542.82M$1.70M-1.69330Gap UpVALNValneva2.018 of 5 stars$6.67-14.4%$17.50+162.4%+2.6%$542.01M$158.54M-51.31700Analyst ForecastAnalyst RevisionHigh Trading VolumeXERSXeris Biopharma3.7409 of 5 stars$3.59-0.3%$5.15+43.5%+25.0%$535.20M$163.91M-7.98290News CoverageMAZEMaze TherapeuticsN/A$12.00+6.0%N/AN/A$525.36MN/A0.00121Gap Up Related Companies and Tools Related Companies ORIC Pharmaceuticals Competitors Rapport Therapeutics Competitors Septerna Competitors Precigen Competitors Stoke Therapeutics Competitors Cullinan Therapeutics Competitors Autolus Therapeutics Competitors Valneva Competitors Xeris Biopharma Competitors Maze Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LXEO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXEO Stock Alerts